Pharming Group
PHAR
3 hedge funds and large institutions have $216K invested in Pharming Group in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
19% less capital invested
Capital invested by funds: $266K → $216K (-$50.5K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$615 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$33.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SBCM
1
Silverberg Bernstein Capital Management
Armonk,
New York
| $186K | – | – | – |
|
|
2
Morgan Stanley
New York
| $29.4K | -$33.1K | -2,800 | -50% |
|
|
3
UBS Group
Zurich,
Switzerland
| $546 | +$615 | +52 | New |
|
PHAR Hedge Fund Activity: Q1 2024 in Review
3 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q1 2024, worth a combined $216K — down 19% from $266K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PHAR positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $615. The largest seller was Morgan Stanley, cutting an estimated $33.1K.
- 3 institutional investors held Pharming Group (PHAR) as of Q1 2024, up from 2 in Q4 2023.
- Funds reported $216K of Pharming Group stock for Q1 2024, down 19% quarter-over-quarter.
- 1 fund opened new Pharming Group positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest Pharming Group buyer in Q1 2024 was UBS Group, an estimated $615 added.
- The largest Pharming Group seller in Q1 2024 was Morgan Stanley, an estimated $33.1K sold.
Based on aggregated 13F filings for Q1 2024.